A226950 Stock Overview
Focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
OliX Pharmaceuticals, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩17,330.00 |
| 52 Week High | ₩21,150.00 |
| 52 Week Low | ₩8,280.00 |
| Beta | 0.81 |
| 11 Month Change | 11.66% |
| 3 Month Change | 90.02% |
| 1 Year Change | 2.12% |
| 33 Year Change | -48.42% |
| 5 Year Change | -5.94% |
| Change since IPO | -47.16% |
Recent News & Updates
Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower
Aug 22
We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt
Jul 22It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks
Jun 25Recent updates
Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower
Aug 22We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt
Jul 22It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks
Jun 25OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely
Apr 13Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year
Feb 17
Shareholder Returns
| A226950 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0.3% | 1.3% | -2.8% |
| 1Y | 2.1% | 44.1% | 4.7% |
Return vs Industry: A226950 underperformed the KR Biotechs industry which returned 45.5% over the past year.
Return vs Market: A226950 underperformed the KR Market which returned 4.8% over the past year.
Price Volatility
| A226950 volatility | |
|---|---|
| A226950 Average Weekly Movement | 13.3% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.5% |
Stable Share Price: A226950's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A226950's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 72 | Dong-Ki Lee | www.olixpharma.com |
OliX Pharmaceuticals, Inc. focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX201A for idiopathic pulmonary fibrosis; OLX301 for age-related macular degeneration; and OLX301D for subretinal fibrosis. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA.
OliX Pharmaceuticals, Inc Fundamentals Summary
| A226950 fundamental statistics | |
|---|---|
| Market cap | ₩294.16b |
| Earnings (TTM) | -₩19.72b |
| Revenue (TTM) | ₩17.90b |
16.4x
P/S Ratio-14.9x
P/E RatioIs A226950 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A226950 income statement (TTM) | |
|---|---|
| Revenue | ₩17.90b |
| Cost of Revenue | ₩222.79m |
| Gross Profit | ₩17.68b |
| Other Expenses | ₩37.40b |
| Earnings | -₩19.72b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.16k |
| Gross Margin | 98.76% |
| Net Profit Margin | -110.18% |
| Debt/Equity Ratio | 166.8% |
How did A226950 perform over the long term?
See historical performance and comparison